Table of Contents
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Drug Class
1.1.2. Regional scope
1.1.3. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Drug Class
2.2.2. Regional outlook
2.3. Competitive Insights
Chapter 3. Liver Cancer Drugs Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Liver Cancer Drugs Market Analysis Tools
3.4.1. Industry Analysis – Porter’s Five Forces
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape
Chapter 4. Liver Cancer Drugs Market: Drug Class Estimates & Trend Analysis
4.1. Liver Cancer Drugs Market: Key Takeaways
4.2. Liver Cancer Drugs Market: Drug Class Movement & Market Share Analysis, 2022 & 2030
4.3. Targeted Therapy
4.3.1. Targeted therapy market estimates and forecasts, 2018 to 2030, (USD Million)
4.4. Immunotherapy
4.4.1. Immunotherapy market estimates and forecasts, 2018 to 2030, (USD Million)
4.5. Chemotherapy
4.5.1. Chemotherapy market estimates and forecasts, 2018 to 2030, (USD Million)
Chapter 5. Liver Cancer Drugs Market: Regional Estimates & Trend Analysis
5.1. Regional Outlook
5.2. Liver Cancer Drugs Market by Region: Key Takeaways
5.3. North America
5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.3.2. U.S.
5.3.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.3.3. Canada
5.3.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4. Europe
5.4.1. UK
5.4.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.2. Germany
5.4.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.3. France
5.4.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.4. Italy
5.4.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.5. Spain
5.4.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.6. Denmark
5.4.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.7. Sweden
5.4.7.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.4.8. Norway
5.4.8.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5. Asia Pacific
5.5.1. Japan
5.5.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.2. China
5.5.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.3. India
5.5.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.4. Australia
5.5.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.5. Thailand
5.5.5.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.5.6. South Korea
5.5.6.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.6. Latin America
5.6.1. Brazil
5.6.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.6.2. Mexico
5.6.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.6.3. Argentina
5.6.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7. MEA
5.7.1. South Africa
5.7.1.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7.2. Saudi Arabia
5.7.2.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7.3. UAE
5.7.3.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
5.7.4. Kuwait
5.7.4.1. Market estimates and forecasts, 2018 – 2030 (Revenue, USD Million)
Chapter 6. Competitive Landscape
6.1. Recent Developments & Impact Analysis, By Key Market Participants
6.2. Market Participant Categorization
6.2.1. Bayer AG
6.2.1.1. Company overview
6.2.1.2. Financial performance
6.2.1.3. Product benchmarking
6.2.1.4. Strategic initiatives
6.2.2. Bristol-Myers Squibb Company
6.2.2.1. Company overview
6.2.2.2. Financial performance
6.2.2.3. Product benchmarking
6.2.2.4. Strategic initiatives
6.2.3. Eisai Co., Ltd.
6.2.3.1. Company overview
6.2.3.2. Financial performance
6.2.3.3. Product benchmarking
6.2.3.4. Strategic initiatives
6.2.4. Exelixis, Inc.
6.2.4.1. Company overview
6.2.4.2. Financial performance
6.2.4.3. Product benchmarking
6.2.4.4. Strategic initiatives
6.2.5. Merck KGaA
6.2.5.1. Company overview
6.2.5.2. Financial performance
6.2.5.3. Product benchmarking
6.2.5.4. Strategic initiatives
Table 1 List of Abbreviations
Table 2 North America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 3 North America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 4 U.S. liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 5 Canada liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 6 Europe liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 7 Europe liver cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 8 Germany liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 9 UK liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 10 France liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 11 Italy liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 12 Spain liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 13 Denmark liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 14 Sweden liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 15 Norway liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 16 Asia Pacific liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 17 Asia Pacific liver cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 18 China liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 19 Japan liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 20 India liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 21 Australia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 22 Thailand liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 23 South Korea liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 24 Latin America liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 25 Latin America liver cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 26 Brazil liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 27 Mexico liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 28 Argentina liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 29 Middle East and Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 30 Middle East and Africa liver cancer drugs market, by region, 2018 - 2030 (USD Million)
Table 31 South Africa liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 32 Saudi Arabia liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 33 UAE liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
Table 34 Kuwait liver cancer drugs market, by drug class, 2018 - 2030 (USD Million)
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
